Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 3/20 | 0.49 |
| ▸ | SMARCA4 | P51532 | 3/20 | 0.49 |
| ▸ | PBRM1 | Q86U86 | 3/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 2/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22777626 | 0.90 | SMARCA2 (0.54) | SMARCA2SMARCA4PBRM1GPR119JAK2 | |
| SCHEMBL22777884 | 0.87 | SMARCA2 (0.43) | SMARCA2SMARCA4PBRM1JAK1 | |
| SCHEMBL32659729 | 0.87 | SMARCA2 (0.43) | SMARCA2SMARCA4PBRM1JAK1 | |
| SCHEMBL22777868 | 0.86 | SMARCA2 (0.48) | SMARCA2SMARCA4PBRM1GPR119JAK2 | |
| SCHEMBL22791037 | 0.84 | PBRM1 (0.40) | SMARCA2SMARCA4PBRM1 | |
| SCHEMBL24461134 | 0.78 | BRD4 (0.56) | SMARCA2SMARCA4PBRM1BTKHSD11B1 | |
| SCHEMBL30382571 | 0.76 | SMARCA2 (0.38) | SMARCA2SMARCA4PBRM1JAK2JAK1 | |
| SCHEMBL22777883 | 0.76 | SMARCA2 (0.38) | SMARCA2SMARCA4PBRM1JAK2JAK1 | |
| SCHEMBL24461244 | 0.74 | BRD4 (0.48) | SMARCA2SMARCA4PBRM1HSD11B1 | |
| SCHEMBL24461790 | 0.74 | SMARCA2 (0.53) | SMARCA2SMARCA4PBRM1GPR119JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | SMARCA2 6/4885SMARCA4 7/4885PBRM1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.